Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajai Nemani

Interventional Pain Medicine Naples, FL Medical Doctor

NPI 1649265539 CMS profile 256369

1865 Veterans Park Dr Ste 101, Ste 100, Naples, FL 34109

Open in the dashboard

General payments

$25,893

218 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ajai Nemani of Naples, FL is reported in the CMS Open Payments database as having received $25,893 across 218 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $561 26
2024 General $531 29
2023 General $12,072 28
2022 General $5,707 38
2021 General $5,446 55
2020 General $407 13
2019 General $1,169 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajai Nemani
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Ajai Nemani were reported at $561. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Ajai Nemani Interventional Pain Medicine median Middle half National median
2019 $1,169 $684 $216–$2,079 $163
2020 $407 $382 $122–$1,109 $114
2021 $5,446 $552 $167–$1,554 $132
2022 $5,707 $605 $187–$1,924 $149
2023 $12,072 $671 $195–$1,915 $160
2024 $531 $684 $206–$1,837 $164
2025 $561 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Spinal Simplicity, LLC $13,950 18 payments
  2. Abbott Laboratories $3,434 83 payments
  3. Omnia Medical, LLC $3,100 1 payment
  4. Boston Scientific Corporation $2,278 35 payments
  5. Nevro Corp. $1,532 24 payments
  6. Collegium Pharmaceutical, Inc. $375 22 payments
  7. Vertos Medical, Inc. $347 15 payments
  8. Medtronic, Inc. $266 6 payments
  9. Nalu Medical, Inc. $146 1 payment
  10. Saluda Medical Americas, Inc. $144 3 payments
  11. Other $320 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,189 201 payments
  2. Consulting Fee $7,850 6 payments
  3. Education $6,190 2 payments
  4. Travel and Lodging $3,664 9 payments
Products named General payments · program years 2019–2025
  1. HA MINUTEMAN G3-R $13,950 18 payments
  2. WAVEWRITER ALPHA $1,433 13 payments
  3. PROCLAIM $973 10 payments
  4. Proclaim IPG $780 13 payments
  5. Senza Spinal Cord Stimulation System $770 14 payments
  6. Omnia $562 7 payments
  7. Superion Indirect Decompression System $415 8 payments
  8. ETERNA $360 20 payments
  9. XTAMPZA $335 20 payments
  10. INTELLIS ADAPTIVESTIM $266 6 payments
  11. Other $3,192 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

347

Median for Interventional Pain Management: 1,220

Drug cost

$12,980

Median for Interventional Pain Management: $39,344

Branded share of claims

40.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 11 $6,180
Morphine Sulfate Er Morphine Sulfate Brand 56 $3,428
Gabapentin Generic 56 $1,184
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 37 $564
Tramadol Hcl Generic 45 $444
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 37 $433
Pregabalin Generic 13 $151
Trazodone Hcl Generic 13 $124
Meloxicam Generic 29 $110
Duloxetine Hcl Generic 13 $109

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$53,771

Of which drugs: $102

Medicare patients

111

Average age 73

Services billed

1,245

55 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Ischemic heart disease 31%
Depression 25%
Chronic kidney disease 20%
Heart failure 18%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 680 $71

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

218 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record